Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in Lantheus Holdings, Inc. $LNTH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH cut its stake in Lantheus by 97.1% in Q4, selling 2,101,558 shares and retaining 61,714 shares (about 0.09% of the company, valued at ~$4.11M).
• Lantheus beat expectations for the quarter with $1.67 EPS versus $1.17 expected and revenue of $406.79M (vs. $367.03M), and set FY2026 guidance of $5.00–$5.25 EPS.
• Analysts hold a consensus rating of "Moderate Buy" with a $88.86 average target (eight Buys, three Holds), and several firms have recently raised price targets—Mizuho to $95 among them.

Universal Beteiligungs und Servicegesellschaft mbH lowered its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 97.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,714 shares of the medical equipment provider's stock after selling 2,101,558 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.09% of Lantheus worth $4,112,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Blue Trust Inc. increased its stake in Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider's stock worth $66,000 after acquiring an additional 230 shares during the last quarter. United Community Bank increased its stake in Lantheus by 15.6% in the 3rd quarter. United Community Bank now owns 1,815 shares of the medical equipment provider's stock worth $93,000 after acquiring an additional 245 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 275 shares during the last quarter. Concurrent Investment Advisors LLC increased its stake in Lantheus by 10.3% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 3,936 shares of the medical equipment provider's stock worth $202,000 after acquiring an additional 366 shares during the last quarter. Finally, Orion Porfolio Solutions LLC increased its stake in Lantheus by 3.9% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 10,010 shares of the medical equipment provider's stock worth $819,000 after acquiring an additional 377 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Price Performance

Shares of Lantheus stock opened at $81.17 on Thursday. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $5.28 billion, a PE ratio of 24.09 and a beta of -0.12. The business's 50-day moving average price is $78.62 and its 200-day moving average price is $67.91. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $108.91.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The firm had revenue of $406.79 million for the quarter, compared to analyst estimates of $367.03 million. During the same period in the prior year, the company earned $1.59 EPS. The company's revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 4.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on LNTH. JonesTrading lowered Lantheus from a "buy" rating to a "hold" rating in a research note on Friday, February 27th. Citizens Jmp increased their price objective on Lantheus from $73.00 to $78.00 and gave the company a "market outperform" rating in a research report on Tuesday, February 24th. Wall Street Zen upgraded Lantheus from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 28th. Citigroup reiterated an "outperform" rating on shares of Lantheus in a research report on Tuesday, February 24th. Finally, Mizuho increased their price objective on Lantheus from $85.00 to $95.00 and gave the company an "outperform" rating in a research report on Monday, April 13th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Lantheus has a consensus rating of "Moderate Buy" and a consensus target price of $88.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.